Clinical Trials Browser

Phase 1 × Withdrawn × Nivolumab × Clear all

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Phase 1 Withdrawn

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT05717140 2025-08-07

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Phase 1 Withdrawn

Melanoma

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05472506 2024-03-15

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04361058 2023-12-05

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

GATA2 Deficiency, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04955262 2021-07-08

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Phase 1 Withdrawn

Melanoma

NCT03920631 2021-03-23

MicroBLITZ

Phase 1 Withdrawn

Lymphoma, B-Cell

NCT04230330 2020-11-05

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Extranodal NK-T-Cell

NCT04315155 2020-10-28

BENEFIT

Phase 1 Withdrawn

Adenocarcinoma

NCT04128020 2020-10-12

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04125719 2020-02-11

PPD1

Phase 1 Withdrawn

Melanoma

NCT03575234 2019-08-28

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03652233 2019-06-20

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Carcinoma, Squamous Cell

NCT03283046 2017-09-20

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT02357732 2015-12-11

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Phase 1 Withdrawn

Melanoma